TOT'HEMA suukaudne lahus Estland - Estlands - Ravimiamet

tot'hema suukaudne lahus

laboratoire innotech international - raud(ii)glükonaat+mangaanglükonaat+vaskglükonaat - suukaudne lahus - 5mg+0,133mg+0,07mg 1ml 10ml 20tk

POLYGYNAX VIRGO vaginaalpehmekapsel Estland - Estlands - Ravimiamet

polygynax virgo vaginaalpehmekapsel

innotech international - nüstatiin+neomütsiin+polümüksiin b - vaginaalpehmekapsel - 6tk

POLYGYNAX vaginaalpehmekapsel Estland - Estlands - Ravimiamet

polygynax vaginaalpehmekapsel

innothera chouzy - nüstatiin+neomütsiin+polümüksiin b - vaginaalpehmekapsel - 100000rÜ+35000rÜ+35000rÜ 6tk

Tezspire Europese Unie - Estlands - EMA (European Medicines Agency)

tezspire

astrazeneca ab - tezepelumab - astma - ravimid hingamisteede obstruktiivsete haiguste, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Simbrinza Europese Unie - Estlands - EMA (European Medicines Agency)

simbrinza

novartis europharm limited - brinsolamiidi, brimonidine tartraat - ocular hypertension; glaucoma, open-angle - oftalmoloogilised vahendid - kõrge silmasisese rõhu (iop) vähenemine avatud nurga glaukoomi või okulaarse hüpertensiooniga täiskasvanud patsientidel, kellel monoteraapia annab iop-i vähesuse.

Teysuno Europese Unie - Estlands - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, oteracil - kõhu neoplasmid - antineoplastilised ained - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

PHYSIONEAL 40 CLEAR-FLEX GLUCOSE 22,7 MG/ML peritoneaaldialüüsilahus Estland - Estlands - Ravimiamet

physioneal 40 clear-flex glucose 22,7 mg/ml peritoneaaldialüüsilahus

oÜ baxter estonia - hüpertoonilised lahused - peritoneaaldialüüsilahus - 2,27% 1500ml 5tk; 2,27% 3000ml 3tk; 2,27% 1500ml 6tk; 2,27% 2000ml 5tk; 2,27% 2500ml 3tk; 2,27% 2500ml 4tk

PHYSIONEAL 40 CLEAR-FLEX GLUCOSE 38,6 MG/ML peritoneaaldialüüsilahus Estland - Estlands - Ravimiamet

physioneal 40 clear-flex glucose 38,6 mg/ml peritoneaaldialüüsilahus

oÜ baxter estonia - hüpertoonilised lahused - peritoneaaldialüüsilahus - 3,86% 2500ml 3tk; 3,86% 4500ml 2tk; 3,86% 2000ml 4tk; 3,86% 5000ml 2tk; 3,86% 1500ml 6tk

PHYSIONEAL 35 CLEAR-FLEX GLUCOSE 38,6 MG/ML peritoneaaldialüüsilahus Estland - Estlands - Ravimiamet

physioneal 35 clear-flex glucose 38,6 mg/ml peritoneaaldialüüsilahus

oÜ baxter estonia - hüpertoonilised lahused - peritoneaaldialüüsilahus - 3,86% 2500ml 4tk; 3,86% 2000ml 5tk; 3,86% 3000ml 3tk

PHYSIONEAL 35 CLEAR-FLEX GLUCOSE 13,6 MG/ML peritoneaaldialüüsilahus Estland - Estlands - Ravimiamet

physioneal 35 clear-flex glucose 13,6 mg/ml peritoneaaldialüüsilahus

oÜ baxter estonia - hüpertoonilised lahused - peritoneaaldialüüsilahus - 1,36% 2000ml 4tk; 1,36% 1500ml 5tk; 1,36% 2500ml 3tk; 1,36% 3000ml 3tk